The Central Government has modified the Drugs Rules, 1945 to incorporate cell or stem cell derived products, gene therapeutic products, and xenografts into the Centrally License Approving Authority framework. This step aims to enhance regulatory oversight of advanced and emerging medical technologies. The amendment broadens the range of critical drugs and biological products under joint regulatory supervision by central and state authorities, aligning with the Drugs and Cosmetics Act that already covers vaccines and other medicines.
The amendment expands the Centrally License Approving Authority (CLAA) Framework to encompass Cell and Stem Cell-derived Products, gene therapeutics, and xenografts. It seeks to establish consistent regulatory standards nationwide for the evolving medical technologies. This move is intended to elevate regulatory standards for emerging technologies, aligning India’s regulatory framework with global best practices and scientific advancements, as stated by the Ministry of Health and Family Welfare.
Cell or Stem Cell derived products, including stem cell-based regenerative treatments and CAR-T cell therapies, are increasingly utilized in treating blood cancers like leukemias and lymphomas. Gene therapeutic products, such as gene replacement and gene editing products, are employed in managing genetic disorders and various cancers. Xenografts, which are animal tissue-derived products like heart valves for transplantation into humans, find applications in cardiology and orthopedics.
Given the complexity and rapid evolution of these medical technologies, they require heightened regulatory scrutiny to ensure patient safety. The government’s initiative underscores its commitment to safeguarding public health while fostering innovation and swift adoption of cutting-edge technologies in the healthcare and life sciences sectors, according to the ministry’s statement.
